Climb Bio CLYM 深 沪
已收盘 04-02 16:00:00 美东时间
6.56
-0.390
-5.61%
华盛通- 最 高7.22
- 今 开6.82
- 成交量 44.13万股
- 最 低 6.42
- 昨 收 6.95
- 总市值 3.13亿
- 52周最高 8.04
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 1.13
- 委 比 -40.60%
- 总股本 4776.80万
- 历史最高 29.69
- 量 比 1.01
- 振 幅 11.51%
- 历史最低 1.05
- 每 手 1
- 风险率 1.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Truist Securities Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $17
Truist Securities analyst Danielle Brill initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $17.
03-18 18:23
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Wedbush Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $12
Wedbush analyst Laura Chico initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $12.
03-05 21:46
Climb Bio Q4 EPS $(0.26) Misses $(0.18) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 46.07 percent. This is a 100 percent decrease over losses of $(0.13) per share from the
03-05 20:13
Climb Bio Q4 R&D expenses rise to USD 13.7 million (+130.5%)
Climb Bio Q4 R&D expenses rise to USD 13.7 million (+130.5%) Climb Bio reported a Q4 2025 net loss of USD 17.5 million and a FY 2025 net loss of USD 59.9 million. Q4 R&D expenses were USD 13.7 million (up 130.6%) and Q4 G&A expenses were USD 5.6 million (up 12.2%), while FY 2025 R&D expenses were US
03-05 20:02
Piper Sandler Initiates Coverage On Climb Bio with Overweight Rating, Announces Price Target of $23
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Climb Bio (NASDAQ:CLYM) with a Overweight rating and announces Price Target of $23.
02-13 17:47
Climb Bio Announces First Patients Dosed In Budoprutug PrisMN Phase 2 Trial In pMN; Anticipates Data-Rich 2026, With Initial Readouts From All Ongoing Budoprutug And CLYM116 Studies
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory
01-08 20:13
